Influence of Serum TGF-β1 and EGFR Levels on the Therapeutic Effect of High-Dose AraC in Patients with Acute Myeloid Leukemia Based on the Decision Curve.
10.19746/j.cnki.issn.1009-2137.2022.02.014
- Author:
Jiang-Zhao ZHANG
1
;
Min LIU
1
;
Zhi-Ping HUANG
2
Author Information
1. Department of Hematology, Jingzhou Central Hospital, Jingzhou 434020, Hubei Province, China.
2. Department of Hematology, Jingzhou Central Hospital, Jingzhou 434020, Hubei Province, China,E-mail: 191060635@qq.com.
- Publication Type:Journal Article
- Keywords:
acute myeloid leukemia;
cytarabine;
epidermal growth factor receptor;
transforming growth factor-β1
- MeSH:
Cytarabine/therapeutic use*;
ErbB Receptors/blood*;
Humans;
Leukemia, Myeloid, Acute/drug therapy*;
Remission Induction;
Transforming Growth Factor beta1/blood*
- From:
Journal of Experimental Hematology
2022;30(2):407-412
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To analyze the influence of serum levels of transforming growth factor-β1 (TGF-β1) and epidermal growth factor receptor (EGFR) on the therapeutic effect of high-dose cytarabine (HD-AraC) in patients with acute myeloid leukemia (AML).
METHODS:98 patients with AML treated in our hospital from January 2019 to June 2020 were selected as the research subjects, all patients were treated with HD-AraC for 1 course of treatment every week. The effect of 2 groups were evaluated during after one course of treatment and divided into effective group and ineffective group, statistical table of baseline data was designed, the baseline data of 2 groups were counted in detail, the baseline data and serum levels of TGF-β1 and EGFR of 2 groups were compared, Logistic regression analysis was used to examine the relationship between the levels of serum TGF-β1, EGFR and the therapeutic effect of HD-AraC in patients with AML, the value of serum TGF-β1 and EGFR levels in predicting the therapeutic effect of HD-AraC in AML patients was analyzed based on ROC curve and decision curve.
RESULTS:After 1 course of treatment, among the 98 patients, 26 cases had complete remission, 38 cases had partially remission and 34 cases no remission, the total effective rate was 65.31% (64/98); after comparing data of 2 groups, Logistic regression analysis showed that the overexpression of serum EGFR before treatment might be a risk factor for the ineffective treatment of HD-AraC in AML patients (OR>1, P<0.05), overexpression of serum TGF-β1 before treatment might be a protective factor for the ineffective treatment of HD-AraC in AML patients (OR<1, P<0.05); the ROC curve results showed that the AUC of serum EGFR and TGF-β1 before treatment in predicting the risk of ineffective HD-AraC treatment in AML patients were >0.70, which had certain predictive value. The decision curve results showed that in the threshold range of 0.15-044, the prediction model combined with serum EGFR and TGF-β1 levels in predicting the net benefit rate of HD-AraC treatment in AML patients was better than that of serum EGFR or serum TGF-β1 alone.
CONCLUSION:The levels of serum TGF-β1 and EGFR affect the therapeutic effect of HD-AraC in patients with AML and increase the risk of ineffective treatment, serum TGF-β1 and EGFR can be used to predict the risk of ineffective HD-AraC treatment in AML patients, and the combined prediction of net benefit rate is higher.
